TapewireFind a company

person · Reporting owner

White Karen Ann

Disclosed activity across 1 company

Tapewire entity
111085
SEC CIK
0001874118

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
GeneDx Holdings Corp.WGS · Entity 1634Chief People OfficerJuly 25, 2023July 27, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GeneDx Holdings Corp.

Report date July 25, 2023 · Filed July 27, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect4,761 Ending reported balance After 2023-07-26 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2023-07-25 · Exercise / conversion · Acquired 137 · Balance 4,822

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

Row 2 · 2023-07-26 · Sale · Disposed 61 · Balance 4,761

F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Restricted Stock UnitSEC Table II · derivative / convertible securityDirect1,091 Reported balance After 2023-07-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2023-07-25 · Exercise / conversion · Disposed 137 · Balance 1,091

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F3: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 09, 2021 Filed Dec 14, 2021 00:11 UTC GeneDx Holdings Corp. SMFR · Entity 1634 GrantRestricted Stock Unit · Derivative 17,964 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-069334 · doc4.xml · derivative · entry 1

White Karen Ann · CIK 0001874118 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,964

Underlying: Class A Common Stock · 17,964 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration, granted pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 9, 2021 (as amended, the "Merger Agreement"), by and among CM Life Sciences, Inc., S-IV Sub, Inc. and Mount Sinai Genomics, Inc. d/b/a Sema4. In addition, in the event that any similar RSUs are forfeited (for example, as a result of the recipient no longer being an employee of the Issuer), the Merger Agreement provides for the shares underlying such forfeited RSUs to become available for issuance to other RSU recipients. Therefore, each RSU also represents to right to receive additional shares of the Issuer's Class A Common Stock from this "forfeiture pool". The number of shares of the Issuer's Class A Common Stock that may be issued to the Reporting Person pursuant to the "forfeiture pool" is not determinable at this time.

F2 · derivative.exercise_price: [cont'd from footnote 1] Any shares of the Issuer's Class A Common Stock ultimately issued to the Reporting Person in respect of each RSU will be reported in a subsequent filing.

F3 · derivative.exercise_date: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 4,491 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 12 quarterly periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date.

F3 · derivative.expiration_date: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 4,491 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 12 quarterly periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date.

Read SEC document
December 01, 2021 Filed Dec 4, 2021 00:00 UTC GeneDx Holdings Corp. SMFR · Entity 1634 Tax withholdingClass A Common Stock 362 $5.51 $1,994.62
Disclosure

SEC source: 0001209191-21-067989 · doc4.xml · nonDerivative · entry 2

White Karen Ann · CIK 0001874118 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,706

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover certain tax obligation in connection with the stock bonus granted to the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.51 to $5.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Read SEC document
December 01, 2021 Filed Dec 4, 2021 00:00 UTC GeneDx Holdings Corp. SMFR · Entity 1634 GrantClass A Common Stock 1,047 $6.05 $6,334.35
Disclosure

SEC source: 0001209191-21-067989 · doc4.xml · nonDerivative · entry 1

White Karen Ann · CIK 0001874118 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,068

F1 · shares: The indicated shares were issued to Reporting Person as a stock bonus in connection with the elimination of Issuer's sabbatical leave program, in which all employees of Issuer hired on or before June 30, 2021 were provided an opportunity to receive a stock bonus in lieu of their continued eligibility to take sabbatical leave. The stock bonus was fully vested as of the date of issuance.

Read SEC document
October 25, 2021 Filed Nov 3, 2021 00:24 UTC GeneDx Holdings Corp. SMFR · Entity 1634 Exercise / conversionRestricted Stock Unit · Derivative 4,503 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-062554 · doc4.xml · derivative · entry 3

White Karen Ann · CIK 0001874118 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,554

Underlying: Class A Common Stock · 4,503 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F3 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Read SEC document
October 25, 2021 Filed Nov 3, 2021 00:24 UTC GeneDx Holdings Corp. SMFR · Entity 1634 SaleClass A Common Stock 1,482 $7.54 $11,174.28
Disclosure

SEC source: 0001209191-21-062554 · doc4.xml · nonDerivative · entry 2

White Karen Ann · CIK 0001874118 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,021

F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Read SEC document
October 25, 2021 Filed Nov 3, 2021 00:24 UTC GeneDx Holdings Corp. SMFR · Entity 1634 Exercise / conversionClass A Common Stock 4,503 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-062554 · doc4.xml · nonDerivative · entry 1

White Karen Ann · CIK 0001874118 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,503

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

Read SEC document
October 01, 2021 Filed Oct 6, 2021 01:46 UTC GeneDx Holdings Corp. SMFR · Entity 1634 GrantRestricted Stock Unit · Derivative 72,057 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-059759 · doc4.xml · derivative · entry 2

White Karen Ann · CIK 0001874118 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,057

Underlying: Class A Common Stock · 72,057 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F1 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Read SEC document
October 01, 2021 Filed Oct 6, 2021 01:46 UTC GeneDx Holdings Corp. SMFR · Entity 1634 GrantEmployee Stock Option (Right to Buy) · Derivative 48,038 $0.00 Strike: $7.62 $0.00
Disclosure

SEC source: 0001209191-21-059759 · doc4.xml · derivative · entry 1

White Karen Ann · CIK 0001874118 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,038

Underlying: Class A Common Stock · 48,038 shares

Expires 2031-09-30

F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Read SEC document
July 22, 2021 Filed Jul 26, 2021 22:52 UTC GeneDx Holdings Corp. SMFR · Entity 1634 GrantStock Option (Right to Buy) · Derivative 206,109 Not disclosed Strike: $1.90 Not disclosed
Disclosure

SEC source: 0001209191-21-048229 · doc4.xml · derivative · entry 1

White Karen Ann · CIK 0001874118 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,109

Underlying: Class A Common Stock · 206,109 shares

Expires 2030-12-21

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F1 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.